Predicting 177Lu-DOTATATE SPECT Derived Red Marrow Dosimetry from Pretherapy 68Ga-DOTATATE PET and Baseline Biomarkers

被引：0
|
作者：
Moreau, Jill [1 ,2 ]
Wang, Chang [1 ]
Wong, Ka Kit [1 ]
Blakkisrud, Johan [1 ,3 ]
Dewaraja, Yuni [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI USA
[2] Wayne State Univ, Detroit, MI USA
[3] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
241724
引用
收藏
页数：4
相关论文
共 50 条
  • [1] 177Lu-DOTATATE Theranostics Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers
    Peterson, Avery B.
    Wang, Chang
    Wong, Ka Kit
    Frey, Kirk A.
    Muzik, Otto
    Schipper, Matthew J.
    Dewaraja, Yuni K.
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 393 - 399
  • [2] Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT
    Zahed, Hanan
    Beauregard, Jean-Mathieu
    Abikhzer, Gad
    Rush, Christopher
    Probst, Stephan
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E12 - E15
  • [3] Comparison of 68Ga-DOTATATE and 177Lu-DOTATATE kinetics in neuroendocrine tumors
    Ilan, E.
    Lubberink, M.
    Sandstrom, M.
    Jahn, U.
    Velikyan, I.
    Andersson, C.
    Fross-Baron, K.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S276 - S277
  • [4] Malignant insulinoma: 18F-DOPA and 68Ga-DOTATATE PET/CT and treatment with 177Lu-DOTATATE
    Erhamamci, S.
    Sager, S.
    Asa, S.
    Uslu, L.
    Akgun, E.
    Sonmezoglu, K.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2020, 39 (06): : 383 - 386
  • [5] Red Bone Marrow Dosimetry and Haematotoxicity in 177Lu-DOTATATE PRRT
    Tshori, S.
    Glasberg, S.
    Luder, D.
    Krausz, Y.
    Gross, D.
    Schwartz, A.
    Freedman, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S775 - S776
  • [6] 177Lu-DOTATATE (Lutathera) Therapy in 68Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor
    Ventura, David
    Roll, Wolfgang
    Kasper, Hans-Udo
    Rahbar, Kambiz
    Stegger, Lars
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : E585 - E587
  • [7] Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors
    Wong, Ka Kit
    Frey, Kirk A.
    Niedbala, Jeremy
    Kaza, Ravi K.
    Worden, Francis P.
    Fitzpatrick, Kellen J.
    Dewaraja, Yuni K.
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (08) : 892 - 900
  • [8] Visual and whole-body quantitative analyses of 68Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE
    Hotta, Masatoshi
    Sonni, Ida
    Thin, Pan
    Nguyen, Kathleen
    Gardner, Linda
    Ciuca, Liliana
    Hayrapetian, Artineh
    Lewis, Meredith
    Lubin, David
    Allen-Auerbach, Martin
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (04) : 296 - 304
  • [9] Bone Metastases Model for Red Marrow Dosimetry during 177Lu-DOTATATE Treatment
    Hagmarker, L.
    Hemmingsson, J.
    Svensson, J.
    Ryden, T.
    van Essen, M.
    Sundlov, A.
    Gleisner, K. Sjogreen
    Gjertsson, P.
    Bernhardt, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S162 - S163
  • [10] Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
    Ortega, Claudia
    Wong, Rebecca K. S.
    Schaefferkoetter, Josh
    Veit-Haibach, Patrick
    Myrehaug, Sten
    Juergens, Rosalyn
    Laidley, David
    Anconina, Reut
    Liu, Amy
    Metser, Ur
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (10) : 1406 - 1414
12345